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Pyrimidine derivatives I (R\ R2, R3 = Cl, Cl, Cl; Cl, OCHa, Cl;
OCH3, OCH3, Cl; OCHa, OCH3, OCHa; NH2, OCHa, Cl; OCHa, NH2,
OCHa; NH2, H, H; H, NH2, H; H, OH, OH; H, Cl, Cl; H, NH2, NH2
resp.), hexahydropyrimidine-4,6-diones II and III (R4= CH3, C2H5,
C3H7, CH2CH = CH2, C4H9), tetrahydropyrimidine-4,6-diones IV (R4
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IV V VI
R5 = 3)4, 5-trimethoxybenzyl
In vitro antibacterial activity of these compounds was tested
against some bacteria strains and compared with that of the well
known bacteriostatic trimethoprim VI.
The activity of compound I (R! = H, R2= R3= OH) was
higher than that of trimethoprim against Sarcina lutea ATCC 9341,
Klebsiella pneumoniae ATCC 10031 and Pseudomonas aerugiosa
NCTC 10490 while the compounds of group IV acted also against
Corynebacterium xerosis NCTC 9755, E. coli ATCC 10536 and Shi-
gella flexneri.
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INTRODUCTION
Continuing our research on the antibacterial activity of 5-(3,4,5-trime-
thoxybenzylj-pyrimidines- and -barbiturates", we have synthesized new groups
of substituted pyrimidines, hexahydropyrimidines, tetrahydropyrimidines and
hydantoins and have tested their antibacterial effect. It is knownš-! that 3,4,5-
-trimethoxybenzyl group represents a substantial subunit in the broad-spe-
ctrum antibacterial drug trimethoprim and, therefore, it was interesting to
study its analogous compounds following the variation of the heterocyclic
moiety. On the other hand, variation of the heterocyclic moiety in this stru-
cture seemed to us a worthwile research objective, since substituted hetero-
cycles themselves possess various biological activitiesš-".
Thus, in the group of 2,4,6-trisubstituted 5-(3,4,5-trimethoxybenzyl)-pyri-
midines (I-X) we have prepared various chloro, methoxy and amino deri-
vatives. In the group of 5-(3,4,5-trimethoxybenzyl)-hexa- (XXIa-XXIh) and
-tetrahydropyrimidine-4,6-diones (XVIIIa-XVIIIe) we have prepared č-alkyl-,
5-alkenyl- or 5-(3,4,5-trimethoxybenzyl)-derivatives, and the analogous series
of 2-methoxyhexahydropyrimidin-4,6-diones (XVIIa-XVIIe). Analogously sub-
stituted hydantoine derivatives (XIXa--XIXe) have been also prepared.
RESULTS
Synthesis of New Compounds
Mono-, di- and trimethoxyderivatives of 5-(3,4,5-trimethoxybenzyl)-pyri-
midine (II-IV) were obtained by methoxylation of 2,4,6-trichloro derivate (I).
As expected", mono and disubstitution occurred easily while the third methoxy
group entered only upon heating in autoclave at temperatures exceeding
100 DC.
Amino-methoxy derivatives VI and VIlI were analogously obtained from
the corresponding amino-chloro-pyrirnidines' V and VII. The corresponding
2- and 4-aminopyrimidines (IX and X) were obtained by catalytic hydro-
dehalogenation of compounds V and VII, using hydrogen in the presence of
Pd/C.
4,6-Diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XVI) was prepared by
amination of the corresponding 4,6-dichloro derivative XV, which in turn
was obtained by chlorination of 4,6-dihydroxy-5-(3,4,5-trimethoxybenzyl)-pyri-
midine (XIV) using phosphorous oxychloride. The necessary intermediate XIV
was obtained from 2-(3,4,5-trimethoxybenzyl)-malondiamide (XIIIf) , with ethyl-
formate in the presence of sodium methylate.
To obtain 5-substituted derivatives of 2-methoxy-5-(3,4,5-trimethoxyben-
zyl)-hexahydropyrimidin-4,6-dione (XVIIa-XVIIe), the corresponding tetrahy-
dropyrimidines (XVIIIa-XVIIIe) and hydantoins (XIXa-XIXe), 2-substituted
esters of 2-(3,4,5-trimethoxybenzyl)-cyanoacetic acid (XIa-XIh) were used as
the starting compounds.
Compounds XIa-XIh were first transferred into the corresponding cyano-
amides XIIa-XIIh then into the malondiamides (XIIIa-XIIIg) by partial
hydrolysis with sodium hydroxyde and hydrogen peroxide in aqueous solution
(Scheme 2). By cyclization of 2-substituted derivatives of 2-(3,4,5-trimethoxy-
benzyl)-malondiamide (XIIIa-XIIIe) with ethylformate and sodium methylate
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(XVIIa-XVIIe) were prepared. Elimination of methanol with hydrogen chlo-
ride in dry ether from compounds XVIIa--XVIIe afforded the corresponding
tetrahydropyrimidine-4,6-diones (XVIIIa-XVIIIe). Malondiamides XIIIa-XIIIe
reacted with sodium hypochlorite in ar! alkaline medium to give 5-substituted
derivatives of 5-(3,4,5-trimethoxybenzyl)-hydantoin (XIXa-XIXe) (Scheme 2).
5-(3,4,5-Trimethoxybenzyl)-hexahydropyrimidine-4,6-dione and its 5-substi-
tuted derivatives (XXIa-XXIh) were prepared by reductive desulfuration of
the corresponding thiobarbituric acids" (XXa-XXh) with the nascent hydrogen
(Scheme 2).
AntibacteriaL Activity
Antibacterial activity of the new compounds and some intermediates in
their preparation, was tested applying the standard disk-diffusion method and
dilution methodš-", The results obtained by disk-method are presented in
Table 1. The activity was tested on a few strains of Gram-positive and Gram-
-negative bacteria and compared to that of well imown bacteriostatic tri-
methoprim, inhibitor of enzyme dihydrofolatereductase (DHFR)4.
Compound I show ed the antibacterial spectrum similar to that of tri-
methoprim, but the level of activity was substantially lower, with the excep-
tion of the comparable activities against Brucella bronchiseptica ATCC 4617
and Staphylococcus aureus of the animal origin. Compounds II-IV exhibited
antibacterial activity against a number of bacterial strains at the concentra-
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SCHEME 2

































































































































































































































































































































































































































































































































126 N. KUJUND2IĆ ET AL.
tion of 25-300 [lg/disk while trimethoprim acted against the same bacteria
already at the concentration of 0.1-25 [lg/disk.
Compound Vacted only against the strain Streptococcus pyogenes of the
animal origin, and in the quantity of 20 [lg/disk.
Compound IX was completely inactive. Compounds XVIIa, XVIIc-XVIIe
acted against Staphylococcus aureus, Bacillus subtilis and Corynebacterium
xerosis similarly as trimethoprim, while they exhibited a much lower activity
against Escherichia coli (200 ug/disk) than trimethoprim (1 [lg/disk).
The activity of the group of compounds XVIIla, XVlIIb and XVlIId
against Gram-negative bacteria is very high, e. g. compound XVIIlb acted
against Escherichia coli, Shigella jlexneri, Klebsiella pneumoniae and Pseudo-
monas aeruginosa already in the quantity of 0.1 lJ.g!disk, while trimethoprim
acted on the same bacteria in the quantity of l[.~g,25 [lg/disk.
Activity of compound XVIIlb on the strains Sarcina lutea and Coryne-
bacterium xerosis is comparable to that of trimethoprim, while its activity
against other strains was somewhat lower.
Compounds XVIII generally exhibited a rather low activity, while com-
pound XIXa was active only against Klebsiella pneumoniae at the level of
25 [lg/disk. Compound XIV exhibited interesting results, i. e. against three
strains of bacteria (Sarcina lutea, Klebsiella pneumoniae and Pseudomonas
aeruginosa) its activity was higher than for trimethoprim, while against other
strains (Bacillus subtilis and Shigella flexneri) the activity was lower. Com-
pounds XVIIa, XVIIc-XVIIe, XVIIlc, XVIIle and XXI were tested by the
dilution method. Some of the results obtained are presented in Table II.
Compounds from group XVII acted in somewhat lower concentrations
against Gram-negative bacteria (50-75 [lg/ml) than against Gram-negative
bacteria (75 [lg/ml), while trimethoprim, used for comparison purposes, dis-
played an action with in the range from 10 to 100 [lg/ml. The best action shown
by compound XVIId. Against Staphylococcus aureus, Micrococcus flavus, Sar-
cina lutea and Pseudomonas aeruginosa it acted in a concentration of 50 [lg/ml
and against other tested strains in a concentration of 75 [lg/ml. Against these
strains trimethoprim acted in concentrations of 50, 10, 10 and 50 [lg/ml,
respecti vely.
Compound XVIIle showed a somewhat better effect than compound
XVlIIc (50-75 [lg/ml), which is with in the limits of trimethoprim action.
Only against Micrococcus flavus and Sarcina lutea trimethoprim showed a
better action (10 [lg/ml) than compound XVIIle.
Compounds from group XXI acted against the strain Streptococcus hae-
molyticus of human origin in a concentration of 10 [lg/ml, and on other strains
in a concentration of 75-200 [lg/ml, weaker than trimethoprim.
DISCUSSION
The results obtained show that 3,4,5-trimethoxybenzyl derivatives of
chlorinated pyrimidines possess a somewhat lower antibacterial effect than
trimethoprim and that no significant altering of the activity takes place if
chlorine is substituted either by methoxy or amino group. Derivatives with
one or two amino group s in positions 2, 4 and 6 of the pyrimidine ring prooved
to be inactive. Derivatives with hydroxy group s in positions 4 and 6 of the




































































































































































































































































































































































































128 N. KUJUNDZIĆ ET AL.
siella pneumoniae and Pseudomonas aeruginosa, and some other strains. Our
findings described here are in accordance with previous results", where only
compounds with the free position 6 of the pyrimidine ring proved to be active.
An apparent exception to this rule is the 4,6-dihydroxypyrimidine derivative
XIV.
The activity of substituted hexahydropyrimidine-4,6-diones (XXIa-XXIh)
is also lower than that of trimethoprim for all the strains tested but Strepto-
coceus haemolytieus of human origin. The activity is noticeably increased on
introduction of 2-methoxy group in hexahydropyrimidine-4,6-dione derivatives
(XVIIa-XVIId). The effect of these compounds against Staphyloeoeeus aureus
is higher than that of trimethoprim, while against Baeillus s1.ibtilis and Coryne-
baeterium xerosis they act at alma st the same level.
Tetrahydropyrimidine-4,6-diones (XVIIIa-XVIIIe) could be regarded as
the most active of all the tested compounds. Their activity again st Sareina
lutea and Corynebacteri1.im xerosis is comparable to that of trimethoprim,
while against Escherichia eoli, Shigella flexneri, Klebsiella pneumoniae and
Pseudomonas aeruginosa their activity is even higher.
Hydantoin XIXa proved to be less active than trimethoprim. Among
Gram-positive bacteria we found Sareina lutea and Corynebacterium xerosis
to be very sensitive to the compounds from the group of tetrahydropyrimidine-
-4,6-diones (XVIIIb and XVIIId) and 4,6-dihydroxypyrimidine (XIV). Besides,
selective action of 2-methoxyhexahydropyridine-4,6-dione (XVIIb) against
Staphylocoeeus aureus and Baeillus subtilis was observed.
In the group of Gram-negative bacteria, Eseherichia coli, Shigella flexneri,
Klebsiella pne1.imoniae and Pseudomonas ae-(uginosa are sensitive to tetra-
hydropyrimidine-4,6-diones (XVIIIa, XVIIIb and XVIIId) and 4,6-dihydroxy-




2,6- Die hloro-4-methoxy- 5-( 3,4,5 - trimethoxy b enzy l)-pyrimidine (II)
Solution of 3.63 g (0.01 mol) of 2,4,6-trichloro-5-(3,4,5-trimethoxybenzyl)-pyri-
midine! (I) and 0.54 g (0.01 mol) of sodium methylate in 10 ml of metha nol is heated
for 1 h at reflux temperature and then stirred for additional 4 hrs at room tempe-
rature. Methanol is evaporated to dryness, the residue suspended in 30 ml water
and the formed crystals sucked off. 3.13 g (87.4%) of crude 2,6-dichloro-4-methoxy-
-5-(3,4,5-trimethoxybenzyl)-pyrimidine is obtained, and recrystallized from diluted
ethanol for analysis purposes.
6-Chloro-2 ,4-dimethoxy-5-( 3,4,5 - trimethoxy b enzy l)-pyrimidine (III)
Solution of 3.63 g (0.01 mol) of 2,4,6-trichloro-5-(3,4,5-trimethoxybenzyl)-pyri-
midine (I) and 1.08 g (0.02 mol) of sodium methylate in 20 ml of methanolis heated
for one hour at reflux temperature and then stirred for additional 4 hrs at room
temperature. Methanol is evaporated to dryness, the residue suspended in 30 ml
water and the formed crystals sucked off. 3.4 g (96.0%) of crude 6-chloro-2,4-di-
methoxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine is obtained and then recrystallized
from diluted ethanol for analysis purposes.
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2,4,6-·Trimethoxy-5-(3,4,5-trimethoxybenzyl)-pY1-imidine (IV)
Solution of 3.6 g (0.01 mol) of 2,4,6-trichloro-5-(3,4,5-trimethoxybenzyl)-pyrimi-
dine (I) and 1.78 g (0.033 mol) of sodium methylate in 30 ml of methanol is heated
in an autoclave for 4 hrs at 100oC. Methanol is evaporated to dryness, the residue
suspended in 30 ml water and the crystals are separated by filtration. 3.42 g (97.7010)
of crude 2,4,6-trimethoxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine is obtained and re-
crystallized from diluted ethanol for analysis purposes.
2-Amino-6-chloro-4-methoxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine (VI)
Mixture of 3.4 g (0.01 mol) of 2-amino-4,6-dichloro-5-(3,4,5-trimethoxybenzyl)-
-pyrimidine! (V), 0.54 g (0.01 mol) of sodium methylate and 10 ml of methanol is
heated for 1 h at reflux temperature and then stirred for additional 4 hrs at room
temperature. Methanol is evaporated, the residue suspended in 30 ml water and the
formed crystal s sucked off.
2.79 g (82.4%) of crude 2-amino-6-chloro-4-methoxy-5-(3,4,5-trimethoxybenzyl)-
-pyrimidine is obtained and recrystallized from diluted ethanol for analysis pur-
poses.
4-Amino-2,6-dimethoxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine (VIlI)
Mixture of 3.4 g (0.01 mol) of 4-amino-2,6-dichlor-5-(3,4,5-trimethoxybenzyl)-
-pyrimidine! (VII), 1.08 g (0.02 mol) of sodium methylate and 20 ml of methanol is
heated for 1 h at reflux temperature and then stirred for additional 4 hrs at room
temperature. Methanol is evaporated, the residue suspended in 30 ml water and the
formed crystals sucked off.
2.75 g (82.5%) of crude 4-amino-2,6-dimethoxy-5-(3,4,5-trimethoxybenzyl)-pyri-
midine is obtained and then recrystallized from diluted ethanol for analysis pur-
poses.
2-Amino-5-(3,4,5-trimethoxybenzyl)-pyrimidine (IX)
Solution of 3.43 g (0.01 mol) of 2-amino-4,6-dichlor-5-(3,4,5-trimethoxybenzyl)-
-pyrimidine'{V) and 0.8 g (0.02 mol) of sodium hydroxide in 80 ml of 800/0 ethanol
in the presence of 1 g of 5010Pd/C is hydrogenated in the hydrogenation apparatus
of the Paar firm under hydrogen pressure of 4 bars and a temperature of 70>°C_
After consumption of an equivalent quantity of hydrogen (0.02 mol), the catalyzer
is sucked off, the filtrate is evaporated to dryness under lowered pressure, the
residue suspended in 20 ml water and the formed crystals sucked off.
2.7 g (98.0010)of crude 2-amino-5-(3,4,5-trimethoxybenzy,l)-pyrimidine is obtained
and recrystallized from diluted ethanol for analysis purposes.
4-Amino-5-(3,4,5-trimethoxybenzyl)-pyrimidine (X)
Solution of 3.43 g (0.01 mol) of 4-amino-2,6-dichloro-5-(3,4,5-trimethoxybenzyl)-
-pyrirnidine'{Vl l) and 0.8 g (0.02 mol) of sodium hydroxide in 80 ml of 80010ethanol
is hydrogenated in the hydrogenation apparatus of the Paar firm in the pres ence
of 1 g of 5010Pd/C under hydrogen pressure of 4 bars and temperature of 700e
until the consumption of an equivalent quantity of hydrogen (0.02 mol). The
catalyzer is sucked off, the filtrate evaporated to dryness under lowered pressure,
the residue suspended in 20 ml water and the formed crystal s sucked off. 2.68 g
(97.5010)of crude 4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidine is obtained and re-
crystallized from diluted ethanol for analysis purposes. Elemental analyses for new
compounds are given in Table III.
2-Substituted 2-(3,4,5-trimethoxybenzyl)-cianoacetamide Derivatives
(XIIa-XIIh)
Into the ethanol solution (150 ml) of one of the esters of 2-substituted 2-(3,4,5-
-trimethoxybenzy.l)-cianoacetic acid" (XIa-XIh. 0.05 mol) gaseous ammonia is intro-
duced until saturation and the obtained reaction mixture is stirred for 5 hrs at
r
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room temperature. Upon ethanol evaporation and residue recrystallization from
ethanol, the corresponding amides of 2,2-disubstituted cianoacetic acid XUa-XUh
are obtained in the yield of 64.9-90.5°/0. Analyses data concerning these compounds
are given in Table IV.
2-Substituted 2-(3,4,5-trimethoxybenzyl)-malondiamide Derivatives
(XIIla-XIIIg)
To 70 ml of 150/0 sodium hydroxide water solution (0.3 mol), 20 ml of 330/0
hydrogen peroxide (0.21 mol) and 0.04 mol of the corresponding cianoacetamide
(XUa-XUg) are added. The obtained reaction mixture is stirred for 6 hours at a
temperature of 60 -c and then cooled to O -c, The formed crystals are sucked off
and recrystallized from ethanol and after that 2,2-disubstituted malondiamides
XIUa-XUIg in the yield of 62.6-74.50/0 are obtained. Analysis data concerning
these compounds are given in Table IV.
4,6-Dihydroxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XIV)
To the solution of 1.2 g (0.022 mol) of sodium methylate in 30 ml of methanol,
1.6 ml (0.022 mol) of ethylformate and 5.6 g (0.02 mol) of 2-(3,4,5-trimethoxybenzyl)-
malondiamide (XUIf) are added. The formed reaction mass is stirred for 6 hours
at reflux temperature, methanol is evaporated, the residue dissolved in cold water
(20 ml) and neutralized with diluted hydrochloric acid until pH 6. The formed
crystals are sucked off and recrystallized from methanol and after that 4,6-dihy-
droxy-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XIV, 3.4 z, 58.50/0)with m. p. 242-244°C
is obtained.
4,6-Dichloro-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XV)
Mixture of 2.9 g (0.01 mol) of cornpound XIV, 18.4 g (0.12 mol) of phosphoroxy-
chloride and 1.7 g (0.014 mol) of N,N-dimethylaniline in 25 ml of benzene is heated
for 2 hours at reflux temperature. Reaction mixture is then evaporated to dryness
under lowered pressure, ice-water (25 ml) is added to the residue and stirred for
an additional half hour. The formed crystals are sucked off and recrystalized from
isopropanole and after that 4,6-dichloro-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XV,
2.7 s, 82,1~/o) with m. p. 111-112 =c is obtained.
4,6-Dicimino-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XVI)
Mixture of compound XV (2.7 g, 0.0082mol) and conc. ammonium water solution
(24 ml) is heated at 130 -c for 6 hours in an autoclave under stirring. After cooling
to room temperature, the residue is sucked off and washed with water. 4,6-Diamino-
-5-(3,4,5-trimethoxybenzyl)-pyrimidine (XVI, 2.1 g, 88.3%) is obtained which is after




Comp. M.p./",C Formula C H N C H N
U 83-84 C15H16Cl2N204 50.19 4.48 7.80 50.16 4.40 8.10
Ul 99--100 C16H19CIN205 54.18 5.40 7.88 54.12 5.10 8.14
IV 99--':100 C17H22N206 58.28 6.33 7.99 58.26 6.24 8.20
VI 188-189 C15H1SClN304 53.04 5.33 12.36 52.81 5.04 12.30
VIlI 189-190 C16H21N305 57.30 6.31 12.53 57.22 6.02 12.70
IX 145-146 C14H17N303 61.08 6.22 15.27 60.94 6.40 15.06
X 141-142 C14H17N303 61.08 6.22 15.27 61.01 5.92 15.52
XI 242-244 C14H12N205 57.53 5.52 9.59 57.42 5.79 9.70
XII 111-112 C14H14CbN203 51.08 4.29 8.51 51.34 4.58 8.74
































































































































































































































































































































































































































































































































































































































132 N. KUJUNDZrC ET AL.
5-Substituted 2-methoxy-5-(3,4,5-tTimethoxybenzyl)-hexahydTopYTimidine-
-4,6-dione DeTivatives (XVIIa-XVIIe)
Into 30 ml of anhydrous methanol 1.2 g (0.02 mol) of sodium methylate is
dissolved and then 1.6 ml (0.022 mol) of ethylformate and 0.02 mol of the corres-
ponding malondiamide (XIIIa-XIIIe) are added. The obtained reaetion mixture is
stirred for 6 hours at reflux temperature, methanol is evaporated, the residue
suspended in 20 ml of eold water and neutralized with diluted hydroehlorie aeid.
The formed erystals are sucked off and recrystallized from methanol. In this way
5-substituted derivati ves of 2-methoxy-5-(3,4,5-trimethoxybenzyl)-hexahydropyrimi-
din-4,6-dione (XVIIa-XVIIe) are obtained in 64.1-75.5% yield (Table V).
5-Substituted 5-(3,4,5-tTimethoxybenzyl)-tetmhyd1'opYTimidine-4,6-dione
Derivatives (XVIIla-XVIIle)
Corresponding 2-methoxy-5,5-disubstituted derivati ves of hexahydropyrimidine-
-4,6-dione (XVIIa-XVIIe, 0.015mol) are dissolved in ether (50 ml), cooled to 0-50C,
saturated with gaseous hydrogen chloride and the obtained reaction mixture is
stirred for an additional hour at the same temperature. The formed crystals are
sucked off, washed with ether and recrystallized from ethanol. 5,5-Disubstituted
derivatives of tetrahydropyrimidin-4,6-dione (XVlIIa-XVIIIe) in the yield of 81.5-
-89.3% are obtained (Table V).
5-Substituted 5-(3,4,5-tTimethoxybenzyl)-hydantoin DeTivatives (XIXa-XIXe)
In 80 ml of sodium hypochlorite water solution containing 8.2 g (0.11 mol)
NaOCI, 4.16 g (0.1 mol) of sodium hydroxide are dissolved and then 0.03 mol of the
corresponding 2-substi tuted 2-(3,4,5-trimethoxybenzyl)-malondiamide (XIIIa-XIIle)
is added. After dissolving, the reaction mixture is stirred for 5 hours at 50oC,
cooled to room temperature and acidified to pR 6 with 10u/uhydrochloric acid. The
formed crystals are sucked off and recrystallized from ethanol and after that the
eorresponding 5-substituted 5-(3,4,5-trimethoxybenzyl)-hydanoin derivatives (XIXa-
-XIXe) in 44.2-51.2% yield are obtained (Table V).
5,5-Disubstituted hexahydTopYTimidine-4,6-dione DeTivatives (XXla-XXlh)
Mixture of the corresponding 5-substituted 5-(3,4,5-trimethoxybenzyl)-thiobar-
bituric acid" (XXa-XXh, 0.006 mol), ethanol (40 ml) and zink in powder form (11.0
g, 0.167 gat) is heated to 35°C and while at that temperature 50 ml (0.32 mol) of
22o/u hydrochloric aeid is added dropwise. Reaction mixture is evaporated until
40 ml volu me and poured into 100 ml water. The formed crystals are sucked off,
washed with 10% sodium bicarbonate solution and recrystallized from isopropanol.
Pure 5-substituted derivati ves of 5-(3,4,5-trimethoxybenzyl)-hexahydropyrimidine-
-4,6-dione (XXIa-XXIh) are obtained, the elemental analyses for which are given
in Table VI.
Biology
Antibacterial activity of the tested compounds has been examined applying
the standard disk-diffusion method and the dilution method described earl.ierš-".
Prior to testing the compounds were dissolved in N,N-dimethylformamide, and the
required concentrations were prepared by dilution phosphate buffer p'H 8.
Two group s of bacteria strains were used: standard strains from the inter-
national collection of test-cultures and some clinical isolates of human origin
(location Zagreb),
The test results were after 18-20 hours incubation in a thermo-chamber at
the air temperature of 37°C. Minimal inhibitory concentrations (M I C) for the
dilution method are expressed in .ug/ml and minimal active quantities (for the
disk method) are given in /-lg per disk. The antibacterial activity of the new
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SAZETAK
Sinteza antibakterijsko djelovanje nekih derivata pirimidina i hidantoina
N. Kujundžić, K. Kovačević, M. Jakovina i B. Glunčić
Sintetizirani su derivati pirimidina I (R1,R2,R3 = Cl, Cl, Cl; Cl, OCH3, Cl; OCHg,
OCH3, Cl; OCH3, OCH3, OCH3; NH2, OCH3, Cl; OCH3, NH2, OCH3; NH2, H, H; H, NH2,
H; H, OH, OH; H, Cl, Cl; H, NH2, NH2 resp.), heksahidropirimidin-4,6-diona II i III
(R4= CH3, C2HS, C3H7, CH2-CH=CH2, C4H9), tetrahidropirimidin-4,6-diona IV (R4
isti) i hidantoina V (R4 isti).
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R = 3} 4, 5-trlmethoxybenzyl
Spojevima je ispitano antibakterijsko djelovanje in vitro prema različitim soje-
vima bakterija i uspoređeno s djelovanjem poznatog bakteriostatika trimetoprima
VI.
Spoj I (R1=H, R2=R3=OH) aktivniji je nego trimetoprim prema Sarcina lutea
ATCC 9341, Klebsiella pneumoniae ATCC 1C031 i Pseudomonas aeruginosa NCTC
10490, dok su spojevi iz grupe IV aktivniji i prema bakterijama spojeva Coryne-
bacterium xerosis NCTC 9755, E.coli ATCC 10536 i Shigella flexneri.
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